204 related articles for article (PubMed ID: 18072725)
1. Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.
Wilbur DS; Hamlin DK; Chyan MK; Brechbiel MW
Bioconjug Chem; 2008 Jan; 19(1):158-70. PubMed ID: 18072725
[TBL] [Abstract][Full Text] [Related]
2. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
[TBL] [Abstract][Full Text] [Related]
3. Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin.
Wilbur DS; Hamlin DK; Meyer DL; Mallett RW; Quinn J; Vessella RL; Press OW
Bioconjug Chem; 2002; 13(3):611-20. PubMed ID: 12009953
[TBL] [Abstract][Full Text] [Related]
4. Streptavidin in antibody pretargeting. 4. Site-directed mutation provides evidence that both arginine and lysine residues are involved in kidney localization.
Wilbur DS; Hamlin DK; Sanderson J; Lin Y
Bioconjug Chem; 2004; 15(6):1454-63. PubMed ID: 15546215
[TBL] [Abstract][Full Text] [Related]
5. Reagents for astatination of biomolecules. 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211.
Wilbur DS; Chyan MK; Hamlin DK; Perry MA
Bioconjug Chem; 2009 Mar; 20(3):591-602. PubMed ID: 19236022
[TBL] [Abstract][Full Text] [Related]
6. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
[TBL] [Abstract][Full Text] [Related]
7. Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.
Wilbur DS; Thakar MS; Hamlin DK; Santos EB; Chyan MK; Nakamae H; Pagel JM; Press OW; Sandmaier BM
Bioconjug Chem; 2009 Oct; 20(10):1983-91. PubMed ID: 19731929
[TBL] [Abstract][Full Text] [Related]
8. Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives.
Wilbur DS; Hamlin DK; Chyan MK; Kegley BB; Quinn J; Vessella RL
Bioconjug Chem; 2004; 15(3):601-16. PubMed ID: 15149189
[TBL] [Abstract][Full Text] [Related]
9. Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds.
Wilbur DS; Chyan MK; Hamlin DK; Kegley BB; Risler R; Pathare PM; Quinn J; Vessella RL; Foulon C; Zalutsky M; Wedge TJ; Hawthorne MF
Bioconjug Chem; 2004; 15(1):203-23. PubMed ID: 14733601
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer.
Li Y; Chyan MK; Hamlin DK; Nguyen H; Vessella R; Wilbur DS
Nucl Med Biol; 2021 Jan; 92():217-227. PubMed ID: 32409263
[TBL] [Abstract][Full Text] [Related]
11. Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.
Wilbur DS; Chyan MK; Nakamae H; Chen Y; Hamlin DK; Santos EB; Kornblit BT; Sandmaier BM
Bioconjug Chem; 2012 Mar; 23(3):409-20. PubMed ID: 22296587
[TBL] [Abstract][Full Text] [Related]
12. Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.
Wilbur DS; Chyan MK; Hamlin DK; Nguyen H; Vessella RL
Bioconjug Chem; 2011 Jun; 22(6):1089-102. PubMed ID: 21513347
[TBL] [Abstract][Full Text] [Related]
13. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
14. Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides.
Wilbur DS
Curr Radiopharm; 2011 Jul; 4(3):214-47. PubMed ID: 22201710
[TBL] [Abstract][Full Text] [Related]
15. Streptavidin in antibody pretargeting. 2. Evaluation Of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity.
Wilbur DS; Hamlin DK; Buhler KR; Pathare PM; Vessella RL; Stayton PS; To R
Bioconjug Chem; 1998; 9(3):322-30. PubMed ID: 9576806
[TBL] [Abstract][Full Text] [Related]
16. Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?
Guerard F; Barbet J; Chatal JF; Kraeber-Bodere F; Cherel M; Haddad F
Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):161-7. PubMed ID: 25752501
[TBL] [Abstract][Full Text] [Related]
17. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.
McDevitt MR; Finn RD; Ma D; Larson SM; Scheinberg DA
J Nucl Med; 1999 Oct; 40(10):1722-7. PubMed ID: 10520715
[TBL] [Abstract][Full Text] [Related]
18. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
Kennel SJ; Mirzadeh S; Eckelman WC; Waldmann TA; Garmestani K; Yordanov AT; Stabin MG; Brechbiel MW
Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
[TBL] [Abstract][Full Text] [Related]
19. Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.
Lingappa M; Song H; Thompson S; Bruchertseifer F; Morgenstern A; Sgouros G
Cancer Res; 2010 Sep; 70(17):6815-23. PubMed ID: 20651254
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.
Wilson JJ; Ferrier M; Radchenko V; Maassen JR; Engle JW; Batista ER; Martin RL; Nortier FM; Fassbender ME; John KD; Birnbaum ER
Nucl Med Biol; 2015 May; 42(5):428-438. PubMed ID: 25684650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
